| Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade BC Miller, DR Sen, R Al Abosy, K Bi, YV Virkud, MW LaFleur, KB Yates, ... Nature immunology 20 (3), 326-336, 2019 | 1709 | 2019 |
| In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target RT Manguso, HW Pope, MD Zimmer, FD Brown, KB Yates, BC Miller, ... Nature 547 (7664), 413-418, 2017 | 1120 | 2017 |
| The epigenetic landscape of T cell exhaustion DR Sen, J Kaminski, RA Barnitz, M Kurachi, U Gerdemann, KB Yates, ... Science 354 (6316), 1165-1169, 2016 | 923 | 2016 |
| CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation J Deng, ES Wang, RW Jenkins, S Li, R Dries, K Yates, S Chhabra, ... Cancer discovery 8 (2), 216-233, 2018 | 665 | 2018 |
| Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF M Quigley, F Pereyra, B Nilsson, F Porichis, C Fonseca, Q Eichbaum, ... Nature medicine 16 (10), 1147-1151, 2010 | 620 | 2010 |
| Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade JJ Ishizuka, RT Manguso, CK Cheruiyot, K Bi, A Panda, A Iracheta-Vellve, ... Nature 565 (7737), 43-48, 2019 | 585 | 2019 |
| CD39 Expression Identifies Terminally Exhausted CD8+ T Cells PK Gupta, J Godec, D Wolski, E Adland, K Yates, KE Pauken, C Cosgrove, ... PLoS pathogens 11 (10), e1005177, 2015 | 434 | 2015 |
| The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells M Kurachi, RA Barnitz, N Yosef, PM Odorizzi, MA DiIorio, ME Lemieux, ... Nature immunology 15 (4), 373-383, 2014 | 377 | 2014 |
| Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity GK Griffin, J Wu, A Iracheta-Vellve, JC Patti, J Hsu, T Davis, D Dele-Oni, ... Nature 595 (7866), 309-314, 2021 | 267 | 2021 |
| PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity MW LaFleur, TH Nguyen, MA Coxe, BC Miller, KB Yates, JE Gillis, ... Nature immunology 20 (10), 1335-1347, 2019 | 192 | 2019 |
| Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans KB Yates, P Tonnerre, GE Martin, U Gerdemann, R Al Abosy, ... Nature immunology 22 (8), 1020-1029, 2021 | 180 | 2021 |
| In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer J Dubrot, PP Du, SK Lane-Reticker, EA Kessler, AJ Muscato, A Mehta, ... Nature Immunology 23 (10), 1495-1506, 2022 | 123 | 2022 |
| A CRISPR-Cas9 delivery system for in vivo screening of genes in the immune system MW LaFleur, TH Nguyen, MA Coxe, KB Yates, JD Trombley, SA Weiss, ... Nature Communications 10 (1), 1668, 2019 | 115 | 2019 |
| The PD-1 pathway regulates development and function of memory CD8+ T cells following respiratory viral infection KE Pauken, J Godec, PM Odorizzi, KE Brown, KB Yates, SF Ngiow, ... Cell reports 31 (13), 2020 | 106 | 2020 |
| Targeting TBK1 to overcome resistance to cancer immunotherapy Y Sun, O Revach, S Anderson, EA Kessler, CH Wolfe, A Jenney, CE Mills, ... Nature 615 (7950), 158-167, 2023 | 87 | 2023 |
| Vaccine-elicited CD4 T cells induce immunopathology after chronic LCMV infection P Penaloza-MacMaster, DL Barber, EJ Wherry, NM Provine, JE Teigler, ... Science 347 (6219), 278-282, 2015 | 86 | 2015 |
| Targeted reconstruction of T cell receptor sequence from single cell RNA-seq links CDR3 length to T cell differentiation state S Afik, KB Yates, K Bi, S Darko, J Godec, U Gerdemann, L Swadling, ... Nucleic acids research 45 (16), e148-e148, 2017 | 80 | 2017 |
| TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response Z Zeng, CJ Wong, L Yang, N Ouardaoui, D Li, W Zhang, S Gu, Y Zhang, ... Nucleic acids research 50 (D1), D1391-D1397, 2022 | 79 | 2022 |
| CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 2018; 8: 216–233. doi: 10.1158/2159-8290 J Deng, ES Wang, RW Jenkins, S Li, R Dries, K Yates, S Chhabra, ... CD-17-0915.[Europe PMC free article][Abstract][CrossRef][Academic Search], 0 | 79 | |
| The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity CK Baumgartner, H Ebrahimi-Nik, A Iracheta-Vellve, KM Hamel, ... Nature 622 (7984), 850-862, 2023 | 76 | 2023 |
Nick HainingAssistant Professor, Harvard Medical SchoolEmail verificata su dfci.harvard.edu